NEW YORK, June 25, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. 

According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company's lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing's syndrome. While the Company touted the expected success of FDA approval, it failed to disclose that the FDA had in fact expressed concerns to Corcept about the adequacy of the Company's clinical development program assessing relacorilant's effectiveness and that relacorilant's New Drug Application faced a material risk of rejection.

If you currently own CORT and purchased prior to October 31, 2024 please contact Sophia Anne Silayan by email at sophiaanne@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™ 

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:

Kuehn Law, PLLC

Justin Kuehn, Esq.

53 Hill Street, Suite 605 

Southampton, NY 11968

justin@kuehn.law 

(833) 672-0814

View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm-302811222.html

SOURCE Kuehn Law, PLLC

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.